BioPharma Credit (BPCR) has recently entered into an agreement to provide up to US$82.5m in the form of a five-year senior secured loan to OptiNose, a Nasdaq-listed, commercial-stage pharma company with its flagship product XHANCE, an FDA-approved nasal spray for the treatment of chronic rhinosinusitis with nasal polyps. The therapy uses the inhaled corticosteroid fluticasone propionate coupled with OptiNose’s proprietary Exhalation Delivery System (EDS) designed to reach deep into the
30 Sep 2019
BioPharma Credit - New debt investment in OptiNose
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioPharma Credit - New debt investment in OptiNose
BioPharma Credit PLC USD (BPCR:LON) | 87.7 0 0.0% | Mkt Cap: 1,084m
- Published:
30 Sep 2019 -
Author:
Milosz Papst -
Pages:
5
BioPharma Credit (BPCR) has recently entered into an agreement to provide up to US$82.5m in the form of a five-year senior secured loan to OptiNose, a Nasdaq-listed, commercial-stage pharma company with its flagship product XHANCE, an FDA-approved nasal spray for the treatment of chronic rhinosinusitis with nasal polyps. The therapy uses the inhaled corticosteroid fluticasone propionate coupled with OptiNose’s proprietary Exhalation Delivery System (EDS) designed to reach deep into the